Burning mouth syndrome in Parkinson's disease: dopamine as cure or cause?
Burning mouth syndrome has been reported as being more common in Parkinson's disease patients than the general population. While the pathophysiology is unclear, decreased dopamine levels and dopamine dysregulation are hypothesized to play a role. We report a patient with Parkinson's disease who developed burning mouth syndrome with carbidopa/levodopa. Our patient had resolution of burning mouth symptoms when carbidopa/levodopa was replaced with a dopamine agonist. Based on our patient's clinical course, in conjunction with earlier studies assessing the relationship between burning mouth syndrome and Parkinson's disease, we discuss a potential role for dopamine in burning mouth syndrome in Parkinson's disease.
Neuromuscular Division, Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA, coon.elizabeth@mayo.edu
Elizabeth A
EA
Coon
Ruple S
RS
Laughlin
D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D052160:Benzothiazoles / Q000627:therapeutic use; D002054:Burning Mouth Syndrome / Q000139:chemically induced*; D002230:Carbidopa / Q000009:adverse effects* / Q000627:therapeutic use; D004298:Dopamine / Q000031:analogs & derivatives; D018491:Dopamine Agonists / Q000009:adverse effects; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D000077487:Pramipexole
D000978:Antiparkinson Agents; D052160:Benzothiazoles; D018491:Dopamine Agonists; D004338:Drug Combinations; C009265:carbidopa, levodopa drug combination; D007980:Levodopa; D000077487:Pramipexole; D002230:Carbidopa; D004298:Dopamine